Drug discovery startup GTN lands £2.1m Seed from Octopus Ventures

May 4, 2018 · uktech.news

Noornew2 898x505

London-based startup GTN has raised £2.1m in Seed funding in a round led by Octopus Ventures to transform drug discovery.

Pentech and existing investor Entrepreneur First also contributed to the round, which will be used to build on GTN’s drug discovery technology.

On average, bringing a new drug to the market costs $2.9bn and takes 15 years, with a high chance of failure; plus an expected 50% drop in R&D output every nine years.

GTN, a female-led company, has developed a technology called Generative Tensorial Networks. It combines and builds upon techniques from machine learning and quantum physics to simulate, filter and discover new molecules. The company says this will help bring efficiencies to the drug development cycle, discovering much-needed medicines for patients with cancer, autoimmune and infectious diseases.

Read Complete Article

RT @bloomingfoundrs: 3 DAYS! Is your spot reserved for the #bloomerama education showcase yet? #education #femalefounders @techdotlondon @T…

London must be the safest and most welcoming city in the world. We’re agreeing a first for our city: a charter of w… https://t.co/com2r8V4Kc

The UK is back as the leading market in Europe for attracting venture capital investments with London #FinTech… https://t.co/5MuGKKOJuJ

Want to help build a digital suitcase for those who love fashion and travel? ✈️ Own Kind are looking for an #intern… https://t.co/LKxr6ouzZj

Composable Infrastructure For Dummies, HPE Special Edition https://t.co/sDfq7W1fhf